NEW YORK (GenomeWeb News) – SDIX reported after the close of the market on Wednesday that its second-quarter revenues fell 10 percent year over year.

The Newark, Del.-based company said that for the three months ended June 30, revenues totaled $5.5 million, down from $6.1 million a year ago. The drop-off was primarily related to the timing of in vitro diagnostic sales, it said, as well as continued weakness in the biopharmaceutical market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.